The US has delayed its planned 100% tariff on Singaporean drug exports, allowing local pharmaceutical firms to seek exemptions.
The US has postponed the implementation of a 100% tariff on branded drugs exported from Singapore, initially set to take effect on 1 October 2025.
According to the Straits Times, this delay allows Singaporean pharmaceutical companies to negotiate potential exemptions with the US administration.
While no new timeline for the tariff’s enforcement was provided, Singapore’s Minister of State for Trade, Gan Siow Huang, noted that companies are awaiting feedback from the US to determine if their plans to expand manufacturing capacity might qualify them for exemptions.
Currently, Singapore’s exports to the US face a baseline tariff of 10%, which is lower compared to other Southeast Asian nations.
Pharmaceuticals account for approximately 13% of Singapore’s exports to the US, with the sector contributing around SGD 4 billion (USD 3.1 billion) annually, most of which comes from branded drug exports.
